In this study, we present new findings that cGAMP combined with OXA can effectively increase OXA sensitivity through the PI3K/AKT/p53 signaling axis, reverse OXA resistance in CRC, and significantly enhance anti-tumor efficacy. This evidence concerns the gene AKT1 and colorectal carcinoma.